Literature DB >> 31997532

Evaluation of functional assays for the diagnosis of heparin induced thrombocytopenia using 5B9, a monoclonal IgG that mimics human antibodies.

Caroline Vayne1,2, Eve-Anne Guéry1, Noémie Charuel2, Joevin Besombes1, Wayne C Lambert1, Jérôme Rollin1,2, Yves Gruel1,2, Claire Pouplard1,2.   

Abstract

BACKGROUND: Serotonin release assay (SRA) is considered as the "gold standard" for detecting pathogenic heparin-induced thrombocytopenia (HIT) antibodies. However, this method is time consuming, expensive, and uses radioelements. Heparin-induced multiple electrode aggregometry (HIMEA), light transmission aggregometry (LTA) with platelet rich plasma (PRP) or washed platelets (WP), adenosine triphosphate (ATP) release, and flow cytometry (FC) are available alternatives.
OBJECTIVES: To evaluate the performance of these assays, comparatively with SRA, for detecting HIT antibodies, using 5B9, a monoclonal IgG fully mimicking human HIT antibodies. PATIENTS/
METHODS: Heparin-dependent platelet activation induced by 5B9 (50/20/10 µg/mL) was evaluated by all assays performed on the same day using platelets from 20 healthy donors. The three methods exhibiting the highest sensitivity to 5B9 were then assessed by testing samples from patients with either likely (n = 10), or indeterminate/unlikely HIT (n = 10).
RESULTS: All methods exhibited good sensitivity for detecting 5B9 50 µg/mL, but only SRA and HIMEA were positive with 100% of donors using 5B9 20 µg/mL, followed by FC (83%). SRA detected 5B9 10 μg/mL with 90% of donors, while HIMEA and FC were positive in 45% and 44% of cases, respectively. Whereas SRA was positive with 9/10 samples from likely HIT, HIMEA and FC were positive with 6 and 7 of them, respectively. Neither SRA nor HIMEA was positive with indeterminate/unlikely HIT samples, while FC was positive or doubtful in three cases.
CONCLUSIONS: Serotonin release assay likely remains the most sensitive and specific assay for detecting platelet activating HIT antibodies, but HIMEA or FC are potential alternatives, despite being less performant.
© 2020 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  assay; diagnosis; heparin; platelet activation; thrombocytopenia

Mesh:

Substances:

Year:  2020        PMID: 31997532     DOI: 10.1111/jth.14749

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

1.  Indeterminate serotonin release assays are associated with a high mortality rate.

Authors:  Shawn Jindal; Christopher Leyton; Fred Cohen; Morayma Reyes Gil; Henny Billett
Journal:  Res Pract Thromb Haemost       Date:  2022-06-14

Review 2.  Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia.

Authors:  Brigitte Tardy; Thomas Lecompte; François Mullier; Caroline Vayne; Claire Pouplard
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

3.  COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies.

Authors:  Justine Brodard; Johanna A Kremer Hovinga; Pierre Fontana; Jan-Dirk Studt; Yves Gruel; Andreas Greinacher
Journal:  J Thromb Haemost       Date:  2021-04-07       Impact factor: 16.036

4.  Anti-platelet factor 4 immunoglobulin G levels in vaccine-induced immune thrombocytopenia and thrombosis: Persistent positivity through 7 months.

Authors:  Samantha J Montague; Christopher W Smith; Clare S Lodwick; Charlotte Stoneley; Matthew Roberts; Gillian C Lowe; William A Lester; Steve P Watson; Phillip L R Nicolson
Journal:  Res Pract Thromb Haemost       Date:  2022-05-04

5.  An Optimized and Standardized Rapid Flow Cytometry Functional Method for Heparin-Induced Thrombocytopenia.

Authors:  Anne Runser; Caroline Schaning; Frédéric Allemand; Jean Amiral
Journal:  Biomedicines       Date:  2021-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.